Emergent BioSolutions (EBS) Net Equity Issued and Repurchased (2023 - 2026)
Emergent BioSolutions (EBS) posted quarterly Net Equity Issued and Repurchased of $400000.0 for Q1 2026, up 140.0% quarter-over-quarter from -$1.0 million in Q4 2025.
Emergent BioSolutions (EBS) Net Equity Issued and Repurchased (2023 - 2026) Analysis & Trends
Emergent BioSolutions' Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $400000.0 for Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $400000.0; the TTM figure through Mar 2026 stood at -$600000.0 (down 400.0% YoY), while the FY2023 annual figure was $8.4 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased for Q1 2026 stood at $400000.0, up from -$1.0 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $400000.0 in Q1 2026, with the low at -$1.0 million in Q4 2025.
- The 3-year median for Net Equity Issued and Repurchased is $200000.0 (2023), against an average of -$133333.3.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 700,000.00 |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 84.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 400,000.00 |
| Mar 31, 2026 | 400,000.00 |
| Dec 31, 2025 | -1.00 Mn |
| Dec 31, 2025 | -1.00 Mn |
| Dec 31, 2023 | 200,000.00 |
| Dec 31, 2023 | 200,000.00 |